Harrow Health is trading 5.2% down now at $38.58 in after-hours trading after August 10, 2026, second-quarter results missed revenue and adjusted EPS expectations; investors appear focused on the headline earnings shortfall.

  • Revenue reached $70.7 million, while the adjusted EPS loss was $0.46.
  • Management reiterated $350 million–$365 million full-year revenue guidance.
  • VEVYE revenue rose approximately 40% sequentially to $29.4 million.